Robin Reschke, Physician Scientist at the University Hospital Heidelberg, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Can we predict immunotherapy toxicity before treatment starts?
Baseline autoantibody profiles predict irAEs and ir-colitis in melanoma treated with immune checkpoint blockade.
Toward safer, personalized checkpoint inhibition.”
Title: Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma
Authors: Robin Reschke, Petra Budde, Hans-Dieter Zucht, Johanna Mangana, Reinhard Dummer, Claudia Pfoehler, Kilian Wistuba-Hamprecht, Benjamin Weide, Lara-Elena Hakim-Meibodi, Friedegund Meier, Carsten Schulz, Jasmin Richter, Manual Bräutigam, Claudia Gutjahr, Peter Schulz-Knappe, Jessica C. Hassel
Read the Full Article on Journal for ImmunoTherapy of Cancer
More posts about Immunotherapy.